Idera Pharmaceuticals Company Profile (NASDAQ:IDRA)

Idera Pharmaceuticals trades on the NASDAQ under the ticker symbol "IDRA."

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) released its quarterly earnings data on Monday, August, 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by $0.03. The firm had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.20 million. Idera Pharmaceuticals had a negative return on equity of 61.09% and a negative net margin of 300.63%. View Idera Pharmaceuticals' Earnings History.

Idera Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, October, 26th 2017. View Earnings Estimates for Idera Pharmaceuticals.

5 brokers have issued 1-year target prices for Idera Pharmaceuticals' stock. Their predictions range from $2.10 to $8.00. On average, they anticipate Idera Pharmaceuticals' stock price to reach $5.02 in the next twelve months. View Analyst Ratings for Idera Pharmaceuticals.

Here are some recent quotes from research analysts about Idera Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Idera Pharmaceuticals, Inc. is a drug discovery and development company that is developing drug candidates to treat cancer and infectious, respiratory, and autoimmune diseases, and for use in combination with therapeutic and prophylactic vaccines. Idera's proprietary drug candidates are designed to modulate Toll-like Receptors, the body's first line of immune defense. Idera's pioneering DNA chemistry expertise enables it to identify drug candidates for internal development and creates opportunities for multiple collaborative alliances. " (8/10/2017)
• 2. Wedbush analysts commented, "IDRA is focused on pursuing an aggressive development strategy for IMO-2125 in light of durable responses in its ongoing Ph 1 study in PD-1 refractory melanoma. We believe the recently presented translational data demonstrating evidence of mechanism support a wider opportunity in improving the response to checkpoint agents in additional immunogenic tumors, as potentially broadening their utility to less immunogenic tumors." (1/31/2017)

Idera Pharmaceuticals saw a decline in short interest in the month of August. As of August 31st, there was short interest totalling 10,685,548 shares, a decline of 10.8% from the August 15th total of 11,982,661 shares. Based on an average daily trading volume, of 706,620 shares, the days-to-cover ratio is presently 15.1 days. Approximately 8.3% of the shares of the company are sold short.

Some companies that are related to Idera Pharmaceuticals include Abeona Therapeutics (ABEO), WAVE Life Sciences (WVE), AC Immune SA (ACIU), ANI Pharmaceuticals (ANIP), Inovio Pharmaceuticals (INO), PDL BioPharma (PDLI), KALA PHARMCTLS (KALA), Celyad SA (CYAD), Adamas Pharmaceuticals (ADMS), Mesoblast Limited (MESO), Voyager Therapeutics (VYGR), Cara Therapeutics (CARA), Agenus (AGEN), Corvus Pharmaceuticals (CRVS), NewLink Genetics Corporation (NLNK), Concert Pharmaceuticals (CNCE), Celldex Therapeutics (CLDX) and Puretech Health PLC (PRTC).

Idera Pharmaceuticals' management team includes the folowing people:

• James A. Geraghty, Independent Chairman of the Board
• Vincent J. Milano, President, Chief Executive Officer, Director
• Youssef El Zein, Independent Vice Chairman of the Board
• Louis J. Arcudi III, Chief Financial Officer, Senior Vice President - Operations, Treasurer, Secretary
• Robert Clayton Fletcher, Senior Vice President - Business Development and Strategic Planning
• Joanna C. Horobin M.D., Senior Vice President, Chief Medical Officer
• Robert A. Doody Jr., Vice President - Investor Relations and Corporate Communications
• William S. Reardon CPA, Lead Independent Director
• Maxine Gowen Ph.D., Director
• Julian C. Baker, Independent Director

Idera Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.47%), Broadfin Capital LLC (2.57%), FMR LLC (2.20%), JPMorgan Chase & Co. (1.55%), State Street Corp (1.19%) and Northern Trust Corp (0.85%). Company insiders that own Idera Pharmaceuticals stock include Invest Corp Pillar, James A Geraghty, Julian Baker, Mark J Casey, Maxine Gowen and Vincent Milano. View Institutional Ownership Trends for Idera Pharmaceuticals.

Idera Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., OxFORD Asset Management LLP, Virtu KCG Holdings LLC, California State Teachers Retirement System, TIAA CREF Investment Management LLC, Nationwide Fund Advisors and New York State Common Retirement Fund. View Insider Buying and Selling for Idera Pharmaceuticals.

Idera Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Vanguard Group Inc., GSA Capital Partners LLP, Alps Advisors Inc., FMR LLC, Northern Trust Corp, State of Wisconsin Investment Board and Teachers Advisors LLC. Company insiders that have bought Idera Pharmaceuticals stock in the last two years include James A Geraghty, Julian Baker, Mark J Casey, Maxine Gowen and Vincent Milano. View Insider Buying and Selling for Idera Pharmaceuticals.

Shares of Idera Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Idera Pharmaceuticals stock can currently be purchased for approximately $2.22.